Atossa (ATOS) CFO granted 578,000 stock options at $1.03

Atossa Therapeutics (ATOS) reported an insider equity award on Form 4.

Rhea-AI Filing Summary

Atossa Therapeutics (ATOS) reported an insider equity award on Form 4. The company’s Chief Financial Officer received a stock option grant to purchase 578,000 shares at an exercise price of $1.03 per share, with a transaction date of October 14, 2025.

The options vest as follows: 25% on October 14, 2026, with the remaining 75% vesting in equal quarterly installments over the following three years, subject to continued service. The options expire on October 14, 2035. Ownership is listed as Direct.

Insider Trade Summary

Grant/Award: 578,000 shares

Grant/Award 1 txn

Insider Daniel Mark James

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	578,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 578,000 contracts (Direct)

Footnotes (1)

1. F1. The options shall vest with respect to 25% on October 14, 2026, with the remaining 75% to vest in equal quarterly installments over the follwing three years, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Atossa Therapeutics (ATOS) disclose on this Form 4?

A stock option grant to the CFO for 578,000 options at an exercise price of $1.03 per share.

Who is the reporting person and their role at ATOS?

The reporting person is the Chief Financial Officer of Atossa Therapeutics.

When was the option grant made and when does it expire?

The grant date is October 14, 2025, and the options expire on October 14, 2035.

What is the vesting schedule for the ATOS CFO’s options?

Vesting is 25% on October 14, 2026, with the remaining 75% vesting in equal quarterly installments over the next three years, subject to continued service.

How many shares underlie the derivative security?

The options cover 578,000 shares of Common Stock.

What is the ownership form for this holding?

The filing lists the ownership form as Direct.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/21/2025 - 04:10 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Daniel Mark James

(Last) (First) (Middle)

C/O ATOSSA THERAPEUTICS, INC.

10202 5TH AVENUE NE SUITE 200

(Street)

SEATTLE WA 98125

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ATOSSA THERAPEUTICS, INC. [ ATOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.03	10/14/2025		A		578,000		(1)	10/14/2035	Common Stock	578,000	$0.00	578,000	D

Explanation of Responses:

1. The options shall vest with respect to 25% on October 14, 2026, with the remaining 75% to vest in equal quarterly installments over the follwing three years, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.

	/s/ Mark James Daniel	10/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.